GxP in pharma in 2026: How Inspectors Evaluate System Control

Wide view of a regulated pharmaceutical manufacturing facility during a quality inspection, illustrating pharmaceutical GxP compliance, GxP inspection readiness, quality risk management, data integrity expectations, and pharmaceutical governance systems.

This article explains how GxP quality systems are assessed during inspections, why gaps in governance and execution lead to repeat audit findings, and how regulated pharma operations strengthen inspection readiness through risk management, data integrity, and lifecycle compliance controls.